butabarbital decreases outcomes of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Intently. Coadministration of CYP3A4 inducers may perhaps decrease sufentanil ranges and efficacy, possibly precipitating withdrawal syndrome in people who definitely have developed Actual physical dependence to sufentan